Lonza strikes deal to acquire Capsugel

15 December 2016

Swiss pharmaceutical and biotech ingredient supplier Lonza (VTX: LONN) announced today that it has now entered into a definitive agreement to acquire US capsule maker Capsugel from private equity firm KKR (NYSE: KKR), as rumored earlier this week.

The transaction is for $5.5 billion in cash, including refinancing of existing Capsugel debt of approximately $2 billion, through a transaction that has been approved by the boards of directors of both Lonza and Capsugel. The transaction will be financed with a combination of debt and equity financing. KKR acquired Capsugel in 2011 from US pharma giant Pfizer (NYSE: PFE) for $2.38 billion.

The deal is expected to close in the second quarter of 2017 and to be accretive to core earnings per share (EPS) in the first full year after closing.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK